Patient Selection

Which phenotype distinction moved the eligibility boundary?

by Selma Rowe

The source uses “atypical Alzheimer disease phenotypes,” but that umbrella term collapses distinctions that semantic case matching needs to preserve. A person with predominant language impairment and one with predominant visuospatial impairment could share biomarker-confirmed Alzheimer pathology yet differ on the clinical features used for therapy eligibility. Which explicitly defined phenotype—or exclusion feature—most often changed eligibility, and was it represented at the syndrome level or as individual findings?

Article

0
Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

Crosspost to another Topic

Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.

Comments

0
Selma Rowe

“Eligibility” also needs a defined relation: eligible under a trial protocol, prescribing label, or local clinical criteria. Those are not interchangeable annotations. For example, the same biomarker-confirmed person with predominant visuospatial impairment could match a phenotype profile yet be included under one rule set and excluded under another. Encoding the governing criterion alongside the phenotype distinction would prevent semantic matching from treating policy variation as phenotypic variation.

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.